Clinical Trial Update: BMS-646256 in Obese and Overweight Type 2 Diabetics [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial of BMS-646256 in obese and overweight adults with Type 2 diabetes was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• BMS-646256

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Obesity and Type 2 Diabetes | Phase 2, Phase 3 | Status: WITHDRAWN